Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic

Anthony S. Russell, James T. Rosenbaum

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

To date, over 2 million patients worldwide have been treated with anti-tumor necrosis factor (TNF) therapies, dramatically improving the treatment outcomes of immune-mediated inflammatory diseases (IMID). Observations from clinicians have identified some curious disconnects between clinical and radiographic outcomes, and the paradoxical occurrence of anti-TNF therapy-induced IMID such as psoriasis or reactivation of uveitis and Crohn's disease. These observations point to the need for a better understanding of the mechanisms underlying the ability of anti-TNF therapies to reduce inflammation and how this is linked to the pathogenesis of IMID. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)53-62
Number of pages10
JournalJournal of Rheumatology
Volume37
Issue numberSUPPL. 85
StatePublished - May 2010

Keywords

  • Anti-tumor necrosis factor
  • Immune-mediated inflammatory diseases
  • Pathologic processes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic'. Together they form a unique fingerprint.

  • Cite this